Choosing among the best pharmaceutical public relations firms starts with a harder question than who has the longest client list: which firm can handle your scientific subject matter, approval process, audiences and commercial goals without separating PR from the way buyers research companies?
Use this guide to compare pharma, biotech and CDMO firms by fit rather than accept a universal rank. The evaluation steps help leaders build a shortlist, test agency claims and compare communications partners on evidence that can be verified during procurement.
Which pharmaceutical PR firm is the best fit?
Compare firms by relevant sector experience, scientific-review workflow, communications capabilities and measurement approach. Start with the agencies below as a research set, then score each one against the same written criteria instead of accepting a publisher’s rank as the final decision.
The shortlist in brief
For broad market research
Use independent directories and published sector lists to identify names, then verify current teams, accounts and conflicts directly.
For integrated healthcare communications
Examine firms that explicitly describe healthcare, digital, social, medical or scientific communications, but test how those disciplines work together on a real assignment.
For a specialist partner
Prioritize demonstrated relevance to your product category, development stage, buyer group and internal review process over agency size alone.
A research set of pharmaceutical and healthcare PR firms
Do not assume one firm is the right choice for every pharmaceutical, biotech and CDMO brief. Compare candidates against the specific assignment, audiences, review requirements and delivery model.
The table below is a diligence starting point. Inclusion means the firm appeared in the supplied healthcare or pharmaceutical search results, except for Percepture, which is included for direct comparison under the same diligence criteria. Inclusion does not certify present capabilities, availability, pricing or performance.
| Firm | Why it enters the research set | What the buyer should verify |
|---|---|---|
| Real Chemistry | Listed first in the supplied O’Dwyer’s healthcare PR ranking snippet. | Current team, category experience, account conflicts and scope ownership. |
| Inizio Evoke | Appears in the supplied O’Dwyer’s and Maricich healthcare agency list snippets. | Which operating team would serve the account and how specialist disciplines are coordinated. |
| Edelman | Appears in the supplied O’Dwyer’s and Maricich healthcare agency list snippets. | Sector-specific staffing, senior involvement and the fit between global resources and the proposed brief. |
| Supreme Group | Appears in the supplied O’Dwyer’s healthcare PR ranking snippet. | Relevant pharmaceutical, biotech or CDMO work and the personnel assigned to delivery. |
| Spectrum | Appears in the supplied O’Dwyer’s healthcare PR ranking snippet. | Scientific-review procedures, audience experience and measurement design. |
| Syneos Health Communications | Its supplied search result describes public relations, digital, social, medical and scientific communications capabilities. | Exact scope, responsible business unit, review controls and integration across disciplines. |
| GCI Health | Appears in the supplied Maricich 2026 healthcare agency list snippet. | Current category experience, proposed team and evidence tied to a comparable communications problem. |
| FleishmanHillard | Appears in the supplied Maricich 2026 healthcare agency list snippet. | Healthcare-specialist staffing, geographic requirements and escalation structure. |
| Miller Geer & Associates | Appears in the supplied Maricich 2026 healthcare agency list snippet. | Fit for the buyer’s company stage, audiences, scope and reporting needs. |
| Ogilvy | Named in the supplied Newsweek healthcare and pharmaceuticals ranking snippet. | The specific healthcare team, relevant work and how strategy moves into day-to-day execution. |
| Finn Partners | Named in the supplied Newsweek healthcare and pharmaceuticals ranking snippet. | The assigned practice, current sector evidence and potential account conflicts. |
| Percepture | Included for direct comparison under the same diligence criteria; this guide does not assign Percepture a rank. | Relevant team, proposed methodology, deliverables, review process and evidence for the buyer’s exact use case. |
For the underlying third-party research, review the O’Dwyer’s healthcare PR rankings, the Newsweek healthcare and pharmaceuticals sector page, the Maricich 2026 healthcare agency guide and the Syneos Health Communications page. Each source uses its own framing, so its order should not replace buyer diligence.
Segment the brief before scoring the agency
Write down which of the following situations most closely describes the assignment before issuing an RFP.
Pharmaceutical company
Examine coordination across corporate communications, brand stakeholders, internal reviewers and multiple audiences. Ask who owns the message architecture, who manages review rounds and how approved language is maintained across channels.
Biotechnology company
Test whether the agency can translate complex source material without overstating it. Give finalists the same sample brief and watch what they question, what they simplify and what they refuse to assume.
CDMO or life-sciences supplier
Ask candidates to explain how they would present technical differentiation to business buyers. Evaluate whether the proposed approach connects subject-matter expertise with discoverable content, earned media and a practical buyer journey rather than treating every announcement as a standalone event.
Percepture’s life-sciences industry page provides company context, while its public relations services and digital PR services give buyers relevant service-level diligence paths.
Use proof before promotion
Agency presentations are designed to persuade. Procurement can use a consistent structure to turn persuasive claims into comparable evidence. For this guide, the Proof Before Promotion method separates questions that are often blended together in a pitch.
Pharmaceutical PR agency scorecard
| Evaluation area | Evidence to request | Warning sign |
|---|---|---|
| Sector fit | Work tied to a similar company stage, audience or communications problem. | Industry logos without an explanation of scope or team involvement. |
| Scientific review | A documented path from source material through specialist review, client approval and final publication. | Vague assurances that the team can “make the science accessible.” |
| Team fit | Names, roles, availability and escalation responsibilities for the people doing the work. | A senior pitch team that disappears from the delivery model. |
| Channel architecture | An explanation of how earned, owned, search and AI-answer visibility support the same narrative. | Separate channel tactics without shared messages or evidence. |
| Measurement | Definitions, reporting cadence, data sources and the decisions each metric will inform. | Large impression figures with no connection to audience quality or business action. |
| Governance | Approval stages, version control, issue escalation and correction procedures. | No clear owner for factual accuracy or approved-language control. |
| Commercial clarity | Scope boundaries, assumptions, exclusions, change controls and pass-through costs. | A price that cannot be mapped to staffing, outputs or responsibilities. |
Score every finalist against the same definitions. Treat a lower score as a prompt to identify the questions, contract terms or internal resources required to make the relationship workable.
Inspect the scientific-review process
Do not settle for “our writers understand healthcare.” Ask the agency to diagram how information moves from an approved source to a draft, through subject-matter and client review, into publication and later correction.
Request a response that identifies owners and handoffs and distinguishes communications review from medical, legal or regulatory judgment. Do not treat marketing personnel as medical authorities based only on work with life-sciences accounts.
- Who identifies the approved source material?
- Who checks scientific interpretation before client review?
- How are comments resolved when reviewers disagree?
- Request a version-control example for reused approved language.
- Who can pause publication when support is incomplete?
- How are corrections documented and distributed?
Test the search-to-trust architecture
Evaluate how each agency would connect earned coverage, corporate pages, search discovery, AI-generated responses and social distribution to a consistent evidence chain.
For this guide, Search-to-Trust architecture means establishing a clear entity and narrative, connecting claims to accessible supporting material, distributing the story through appropriate channels and making the resulting evidence easy to find. It is a decision framework, not a claimed search-engine ranking factor.
When AI-answer visibility belongs in the brief, review Percepture’s generative engine optimization services. When the assignment spans PR, search, content and paid distribution, the omnichannel marketing service is the more relevant diligence path.
Compare scope and investment before the pitch
Use published pricing context to define the workstreams and assumptions you want every finalist to address.
Questions to put in the RFP
- Which part of this brief is most likely to fail? Ask each finalist to identify likely failure points rather than simply mirror the request.
- Which people will do the work? Request names, roles, expected involvement and escalation coverage.
- How will scientific material be reviewed? Ask for a workflow and a sample responsibility matrix.
- What evidence supports each proposed case example? Separate the agency’s work from the client’s wider market results.
- How will conflicts be identified and managed? Define what constitutes a conflict for your category and business model.
- What is excluded from the fee? Surface production, research, travel, distribution, monitoring and pass-through assumptions.
- How will PR connect with owned content and search discovery? Look for one message system rather than parallel activity calendars.
- What happens when evidence is incomplete? Ask whether the process includes escalation, revision or a publication pause.
How to make the final decision
Reduce the shortlist to firms that can show relevant people, a clear review process and evidence appropriate to the brief. Then use a structured working session instead of another credentials presentation.
Give each finalist the same bounded scenario. Ask for the questions they would investigate, the stakeholders they would involve, the evidence they would require and the first decisions they would make. Do not request free speculative campaign work; evaluate judgment, process and fit.
Finally, document why the selected firm won. Use that record as a baseline for later performance reviews.
Frequently asked questions
How were the pharmaceutical public relations firms evaluated?
The firms were assembled from the supplied healthcare and pharmaceutical search results, with Percepture included for comparison under the same diligence criteria. This guide does not convert third-party lists into a universal ranking; it applies a buyer-focused evaluation framework covering sector fit, scientific review, team fit, channel architecture, measurement, governance and commercial clarity.
Which pharmaceutical PR firm is best for a different use case or budget?
Define the assignment, required team, audiences, geography, internal resources and scope first. Then request comparable proposals and evaluate the delivery team rather than relying on list position.
What proof should a buyer verify before choosing a firm?
Verify the proposed team, relevant scope of work, scientific-review workflow, references the firm is authorized to provide, measurement definitions, conflict process, fee assumptions and exclusions.
How current are the pricing, capabilities, rankings and client evidence?
This article does not assert current competitor pricing or client rosters. Third-party list appearances reflect the supplied search materials, and buyers should verify current capabilities, personnel, conflicts and commercial terms directly with each finalist.
Build a defensible pharmaceutical PR shortlist
Bring Percepture your brief, internal review constraints and buyer priorities for a focused PR and search strategy discussion.
Reference image
About Bob Generale
Bob Generale is President of Percepture. Connect with Bob on LinkedIn.
